ライフサイエンスコーパス: daytime sleepiness

1 time sleepiness) to 24 points (high level of daytime sleepiness).

2 nge from 0-24, with values <10 suggesting no daytime sleepiness).

3 epiness Scale (ESS-IR) was used to assess of daytime sleepiness.

4 ude hypothalamic injury, with inactivity and daytime sleepiness.

5 out (n=144) complaints of frequent excessive daytime sleepiness.

6 ict important consequences such as excessive daytime sleepiness.

7 ould prove useful in prediction of excessive daytime sleepiness.

8 may reduce sleep fragmentation and excessive daytime sleepiness.

9 and covariation of obesity with snoring and daytime sleepiness.

10 s and one important outcome, the severity of daytime sleepiness.

11 eep are a well recognized cause of excessive daytime sleepiness.

12 insufficient sleep duration, and adolescent daytime sleepiness.

13 ine whether dietary intervention may improve daytime sleepiness.

14 nd, conversely, of higher BMI on snoring and daytime sleepiness.

15 fants, whereas 14.7% of adolescents endorsed daytime sleepiness.

16 p less than recommended without experiencing daytime sleepiness.

17 cal arousal, often associated with excessive daytime sleepiness.

18 This improves daytime sleepiness.

19 essing sleep quality, insomnia symptoms, and daytime sleepiness.

20 clude loud snoring, nocturnal awakening, and daytime sleepiness.

21 ry disease (CAD), many of whom do not report daytime sleepiness.

22 arding the relationship between mild OSA and daytime sleepiness.

23 quantity, poor sleep quality, and excessive daytime sleepiness.

24 lt in transient but substantial increases in daytime sleepiness.

25 nsomnia, delayed sleep habits, and excessive daytime sleepiness.

26 a sleep study for patients with unexplained daytime sleepiness.

27 ) display significant sleep disturbances and daytime sleepiness.

28 p apnea is a common disease, responsible for daytime sleepiness.

29 s than the recommended 8-10 h and 18% report daytime sleepiness.

30 a nearly significant decrease in subjective daytime sleepiness.

31 idence interval): 2.97 (2.65-3.34)), regular daytime sleepiness (2.66 (2.34-3.01)), and regular insom

32 n 0.53 and 1.33; P < 0.001 for all domains), daytime sleepiness (-2.92; P < 0.001), mood state (-4.24

33 owed high risk for OSAS, 46.3% had excessive daytime sleepiness, 41.5% were positive for both the Bq

34 n of sleep-disordered breathing or excessive daytime sleepiness, a formal sleep assessment is reasona

35 Excessive daytime sleepiness affected 32% of the patients, sometim

36 eads to annoyance, disturbs sleep and causes daytime sleepiness, affects patient outcomes and staff p

37 ea-hypoxia index [AHI] >=5) plus symptoms of daytime sleepiness among adults aged 30 to 70 years was

38 riance in insomnia, 82.7% of the variance in daytime sleepiness and 82.3% of the variance in anxiety

39 urologic disorder characterized by excessive daytime sleepiness and abnormal manifestations of REM sl

40 er marked by chronic, debilitating excessive daytime sleepiness and can be associated with cataplexy,

41 agnostic features of the disorder (excessive daytime sleepiness and cataplexy), effects on cognitive

42 t (REM) sleep, is characterized by excessive daytime sleepiness and cataplexy, a loss of muscle tone

43 y type 1 (NT1) is characterized by excessive daytime sleepiness and cataplexy, accompanied by sleep-w

44 an sleep disorder characterized by excessive daytime sleepiness and cataplexy.

45 litating disorder characterized by excessive daytime sleepiness and cataplexy.

46 colepsy, which is characterized by excessive daytime sleepiness and cataplexy.

47 were significantly more likely to experience daytime sleepiness and dozing during daytime activities.

48 isordered breathing (SDB) is associated with daytime sleepiness and impaired quality of life.

49 Therapeutic NCPAP reduces excessive daytime sleepiness and improves self-reported health sta

50 )) and between increased levels of excessive daytime sleepiness and increased measures for adiposity

51 he impaired sleep pattern and the consequent daytime sleepiness and mood changes.

52 ked to report their sleep duration, quality, daytime sleepiness and nap frequency and duration on a t

53 Sleep quality was significantly related to daytime sleepiness and occupational cognitive failures,

54 roducing, respectively, narcolepsy excessive daytime sleepiness and poor sleep quality.

55 efits, and substantially improving excessive daytime sleepiness and quality of life.

56 brain volumes than both short sleepers with daytime sleepiness and sleep problems (n = 1742) and par

57 Here, we show that daytime sleepiness and sleep problems are more strongly

58 weakly if at all related brain health, while daytime sleepiness and sleep problems may show somewhat

59 th Sleepiness Scale (ESS) was used to assess daytime sleepiness and standardized questionnaires asses

60 dy aimed to explore the relationship between daytime sleepiness and the risk of ischemic stroke and v

61 Daytime sleepiness and time to fall asleep decreased dur

62 ance syndrome (UARS) is defined by excessive daytime sleepiness and tiredness, and is associated with

63 he basis of characteristic history (snoring, daytime sleepiness) and physical examination (increased

64 leep, 1.47 (95% CI, 1.39-1.56) for excessive daytime sleepiness, and 1.44 (95% CI, 1.36-1.53) for res

65 variance in obesity, 40% of the variance in daytime sleepiness, and 23% of the variability in self-r

66 e evaluated sleep characteristics, excessive daytime sleepiness, and chronotype using the Pittsburgh

67 with self-reported parental sleep duration, daytime sleepiness, and dozing among employed adults.

68 leep restriction, irregular sleep schedules, daytime sleepiness, and elevated risk for sleep disturba

69 reasoning, as well as insomnia, depression, daytime sleepiness, and headaches), 2 ("confusion-ataxia

70 ummarized abnormal sleep duration, excessive daytime sleepiness, and insomnia complaints ([Formula: s

71 and patient-reported measures of depression, daytime sleepiness, and quality of life.

72 eathe, and cough or loud snoring), excessive daytime sleepiness, and reduced vigor during the camp.

73 ale score, the visual analog scale score for daytime sleepiness, and sleep log-derived and actigraphy

74 We also characterized mood states, daytime sleepiness, and sleep quality by questionnaires.

75 sal congestion, headache, sleep disturbance, daytime sleepiness, and snoring.

76 ring sleep are not associated with excessive daytime sleepiness, and therefore appear unlikely to con

77 ence increased nocturnal activity, excessive daytime sleepiness, and weight loss.

78 ed (1) the prevalence of insomnia, excessive daytime sleepiness, anxiety and depression among African

79 of the clinical features (i.e., significant daytime sleepiness, anxiety and depression symptoms, pot

80 There was no difference in daytime sleepiness, anxiety, depression, impulsive-compu

81 and fatigue (aOR, 1.59; 95% CI, 1.16-2.19), daytime sleepiness (aOR, 1.81; 95% CI, 1.28-2.55), or in

82 r data show that: (1) poor sleep quality and daytime sleepiness are problems common to all types of I

83 Self-reported daytime sleepiness associated with increased risk for al

84 ervous system disorders, including excessive daytime sleepiness, attention deficit hyperactivity diso

85 This study supports the notion that daytime sleepiness, but not nighttime sleeping duration,

86 Excessive daytime sleepiness can be evaluated with both subjective

87 a sleep disorder characterized by excessive daytime sleepiness, cataplexy, and other pathological ma

88 It is characterized by daytime sleepiness, cataplexy, and striking transitions

89 ological disorder characterized by excessive daytime sleepiness, cataplexy, hypnagonic hallucinations

90 ns of SH (insomnia symptoms, sleep duration, daytime sleepiness, chronotype, and sleep medication) we

91 quality of life, include insomnia, excessive daytime sleepiness, circadian disorders, obstructive sle

92 The complaint of excessive daytime sleepiness, commonly encountered in neurological

93 state, anxiety and depressive symptoms, and daytime sleepiness compared with conservative treatment.

94 ; P =.001) and reduced insomnia severity and daytime sleepiness compared with TAU (insomnia severity

95 r nocturnal-assist servoventilation improves daytime sleepiness compared with the control.

96 eep duration, insomnia symptoms, chronotype, daytime sleepiness, daytime napping, ease of getting up

97 The prevalence of excessive daytime sleepiness, defined as an ESS score >/= 11, incr

98 ea/hypopnea syndrome can experience residual daytime sleepiness despite regular use of nasal continuo

99 Perceived sleep quality and daytime sleepiness did not change over the course of the

100 Excessive daytime sleepiness (EDS) affects 10-20% of the populatio

101 polysomnography with complaints of excessive daytime sleepiness (EDS) and clinically suspected obstru

102 timulants (e.g., modafinil) reduce excessive daytime sleepiness (EDS) and sodium oxybate (gammaaminob

103 ted by exploring the links between excessive daytime sleepiness (EDS) and vulnerability to infectious

104 the treatment of disorders such as excessive daytime sleepiness (EDS) as well as other sleep or cogni

105 e the safety and efficacy of LT on excessive daytime sleepiness (EDS) associated with PD.

106 We assessed whether excessive daytime sleepiness (EDS) at baseline was associated with

107 Excessive daytime sleepiness (EDS) can be caused by insufficient s

108 Excessive daytime sleepiness (EDS) is a public health issue.

109 Excessive daytime sleepiness (EDS) is common and disabling in Park

110 nd snoring and between obesity and excessive daytime sleepiness (EDS), although for the most part the

111 sleep-wake cycle characterized by excessive daytime sleepiness (EDS), cataplexy, nighttime sleep dis

112 The percentage of patients with normalized daytime sleepiness (Epworth score < 10) was significantl

113 (Pittsburgh Sleep Quality Index [PSQI]) and daytime sleepiness (Epworth Sleepiness Scale [ESS]).

114 daytime sleepiness, patients with excessive daytime sleepiness (Epworth Sleepiness Scale score >/=10

115 Patients with self-reported daytime sleepiness (Epworth Sleepiness Scale score >10)

116 d OSA (apnea-hypopnea index >/=15/h) without daytime sleepiness (Epworth Sleepiness Scale score <10)

117 quality (Pittsburgh Sleep Quality Index) and daytime sleepiness (Epworth Sleepiness Scale), and circa

118 ess (Perceived Stress Scale; PSS), excessive daytime sleepiness (Epworth Sleepiness Scale; ESS), depr

119 ere habitual snorers, 18% reported excessive daytime sleepiness (ESS > or = 11), and 29% were obese (

120 In multivariate linear regression, daytime sleepiness (ESS score > 10), was the most signif

121 der narcolepsy is characterized by excessive daytime sleepiness, fragmentation of nighttime sleep, an

122 Excessive daytime sleepiness has emerged as one of the most common

123 Daytime sleepiness impairs cognitive ability, but recent

124 normalizes sleep architecture, and decreases daytime sleepiness in abstinent cocaine users.

125 Excessive daytime sleepiness in CD patients may be driven by facto

126 fect of morning-dosed modafinil on sleep and daytime sleepiness in chronic cocaine users.

127 erence to the DASH-style diet and scores for daytime sleepiness in crude model (beta= -0.12; P=0.005)

128 Here, we identify 42 loci for self-reported daytime sleepiness in GWAS of 452,071 individuals from t

129 p apnea (CSA) is not usually associated with daytime sleepiness in heart failure or atrial fibrillati

130 effect of a genetic risk score of 42 SNPs on daytime sleepiness in independent Scandinavian cohorts a

131 distinct differential diagnosis of excessive daytime sleepiness in older adults.

132 a that self-reported symptoms of snoring and daytime sleepiness in older men have a genetic basis tha

133 ssessing multiple risk factors for excessive daytime sleepiness in older subjects (mean age, 78 years

134 ilation produces an improvement in excessive daytime sleepiness in patients with Cheyne-Stokes breath

135 wake-promoting effects, for the treatment of daytime sleepiness in patients with moderate to severe o

136 nct treatment for the management of residual daytime sleepiness in patients with obstructive sleep ap

137 gmentation (SF) appear to underlie excessive daytime sleepiness in patients with sleep apnea (OSA).

138 The etiology of excessive daytime sleepiness in patients with sleep-disordered bre

139 y of modafinil for the treatment of residual daytime sleepiness in such patients.

140 ep duration, insomnia symptoms and excessive daytime sleepiness in the UK Biobank (n = 112,586).

141 ommon medical disorder that causes excessive daytime sleepiness, increasing the risk for drowsy drivi

142 ma associated with atopy, fatigue, excessive daytime sleepiness, insomnia, and only 0 to 3 nights of

143 orexia nervosa, chronotype, daytime napping, daytime sleepiness, insomnia, and sleep duration.

144 re seen by neurologists, including excessive daytime sleepiness, insomnia, narcolepsy, rapid eye move

145 Rationale: Excessive daytime sleepiness is a common disabling symptom in obst

146 Daytime sleepiness is among the most common symptoms, bu

147 Daytime sleepiness is an independent risk factor for str

148 Sleep disturbance resulting in daytime sleepiness is common in patients with NAFLD, but

149 We aimed to assess whether daytime sleepiness is independently associated with redu

150 Excessive daytime sleepiness is typically the most frequent compla

151 re (CPAP), but its value in patients without daytime sleepiness is uncertain.

152 ESS score > 10, indicative of excessive daytime sleepiness, is an independent predictor of reduc

153 Preliminary evidence suggests that daytime sleepiness may predate clinical diagnosis of Par

154 [SE] difference, -0.42 [0.09], P < .001) and daytime sleepiness (mean [SE] difference, -0.24 [0.09],

155 Secondary endpoints included changes in daytime sleepiness, mood state, anxiety, and depression.

156 ypertension, cardiovascular disease, stroke, daytime sleepiness, motor vehicle accidents, and diminis

157 BI in females and WDR27 in males), excessive daytime sleepiness (near AR-OPHN1) and a composite sleep

158 on in patients with NAFLD, but the effect of daytime sleepiness on HRQoL in NAFLD is unclear.

159 ho reported to sleep <6 h did not experience daytime sleepiness or sleep problems/disturbances interf

160 nfidence interval (CI) 1.18-3.00), excessive daytime sleepiness (OR = 1.49, 95% CI 1.04-2.13), low sl

161 11-2.10) (P = .009, I2 = 74%), and excessive daytime sleepiness (OR, 2.27; 95% CI, 1.54-3.35) (P < .0

162 ted OR, 2.65; P=0.023), those with excessive daytime sleepiness (OR, 2.51; P=0.037), and those with >

163 14-1.88) (P = .003, I2 = 76%), and excessive daytime sleepiness (OR, 2.72; 95% CI, 1.32-5.61) (P = .0

164 es such that eczema associated with fatigue, daytime sleepiness, or insomnia was associated with even

165 ilability and fatigue, depression, excessive daytime sleepiness, or rapid eye movement sleep behaviou

166 menopausal women with complaints of snoring, daytime sleepiness, or unsatisfactory sleep.

167 Daytime sleepiness (Osler test) was measured before and

168 igraphy measured duration and fragmentation, daytime sleepiness, overall quality, self-reported durat

169 Compared with PD patients without excessive daytime sleepiness, patients with excessive daytime slee

170 However, effects on daytime sleepiness, perceived sleep quality, and daytime

171 measures included CBTI use, sleep, insomnia, daytime sleepiness, safety, anxiety, frailty, and qualit

172 ation between adherence to the DASH diet and daytime sleepiness score in adolescent girls.

173 the correlation between DASH-style diet and daytime sleepiness score, we applied logistic regression

174 rrelation between adherence to DASH diet and daytime sleepiness score.

175 Daytime sleepiness should be considered as a contributin

176 However, individual daytime sleepiness signals vary in their associations wi

177 s and animals lacking orexin neurons exhibit daytime sleepiness, sleep attacks, and state instability

178 ty in falling asleep, restlessness of sleep, daytime sleepiness, sleep disturbance, and sleep duratio

179 Insomnia Severity Index were used to assess daytime sleepiness, sleep quality and insomnia symptom s

180 included sleep duration, time awake in bed, daytime sleepiness, sleep talking, sleepwalking, night t

181 Test accuracy, excessive daytime sleepiness, sleep-related and general health-rel

182 onotype (ADGRL4, COL6A3, CLK4 and KRTAP3-3), daytime sleepiness (ST3GAL1 and ANKRD12), daytime nappin

183 quantity, poor sleep quality, and excessive daytime sleepiness, studied according to an a priori pro

184 onclude that within a group of patients with daytime sleepiness, suspected OSA, and a normal RDI, the

185 In patients with OSA without daytime sleepiness, the prescription of CPAP compared wi

186 Active treatment reduced excessive daytime sleepiness; the mean Osler change was +7.9 minut

187 t, and carefully monitor changes in mood and daytime sleepiness throughout the intervention.

188 s Scale (ESS) score, which ranges from 0 (no daytime sleepiness) to 24 points (high level of daytime

189 phalopathy might be unable, due to excessive daytime sleepiness, to accumulate the need/ability to pr

190 hort and long sleep durations, and excessive daytime sleepiness) utilizing the Million Veteran Progra

191 4.9 + 3.2, chronotype was 63.6 +/- 10.8 and daytime sleepiness was 7.4 +/- 4.8.

192 Daytime sleepiness was also associated with NC (P = 0.02

193 Only daytime sleepiness was more common for those receiving a

194 The prevalence of insomnia and daytime sleepiness was not significantly higher compared

195 Daytime sleepiness was trichotomized using previously re

196 abnormal rapid eye movement (REM) sleep and daytime sleepiness, was examined using the canine model.

197 treatment) and OSA concomitant with habitual daytime sleepiness were estimated using repeated-measure

198 This condition causes recurrent insomnia and daytime sleepiness when the rhythms drift out of phase w

199 e disorder mainly characterised by excessive daytime sleepiness, with prolonged night-time sleep and

200 Modafinil significantly improved daytime sleepiness, with significantly greater mean chan

201 Both the MAD and CPAP improved daytime sleepiness, with the between-group difference si

202 nea or >/= 2 hallmarks of OSA: loud snoring, daytime sleepiness, witnessed apnea, and hypertension.